Complement Dependent Cytoxicity | Abzena

Complement-Dependent Cytotoxicity (CDC)

CDC is the mechanism by which antibody-coated target cells recruit and activate components of the complement cascade, leading to the formation of a Membrane Attack Complex (MAC) on the cell surface and subsequent cell lysis.

In our assay, target-expressing cells are incubated with an antibody or ADC, in the presence of human serum containing either active or heat-inactivated complement. Dead-cell protease activity, which is released from cells that have lost membrane integrity, is measured as an indicator of cell lysis.

Working with Abzena

Abzena’s undertakes bioassays on behalf of clients as standalone projects or as part of larger development projects. We focus on developing the correct bioassay to help you understand your molecule and will help guide you in the correct.

To get more information, a quote or to schedule a teleconference please contact us.

CDC Assay Ramos Target Cells
Rituximab induces dose-dependent lysis of CD20-expressing Ramos cells in the presence of Normal Human Serum (NHS). This effect is inhibited upon heat inactivation of the serum (HI NHS), confirming complement-mediated lysis.
Interested in our services? Get In Touch